Jennison Associates
TRML

Jennison Associates’s Tourmaline Bio TRML Stock Holding History

Jennison Associates’s Portfolio TRML Stock Details TRML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-118,487
Closed -$1.8M – 633
2025
Q1 		$1.8M Sell
118,487
-727,313
-86% -$11.7M ﹤0.01% 443
2024
Q4 		$17.2M Sell
845,800
-306,173
-27% -$7.71M 0.01% 357
2024
Q3 		$29.6M Buy
1,151,973
+24,282
+2% +$405K 0.02% 302
2024
Q2 		$14.5M Buy
1,127,691
+12,440
+1% +$200K 0.01% 355
2024
Q1 		$25.5M Buy
+1,115,251
New +$39.3M 0.02% 318

Other funds holding TRML

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
QF
QVT Financial New York $1.27B AUM 148.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $369M AUM 78.25% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return